Very excited to share our new study measuring clinical specificity of #immunoglobulin based high-throughput sequencing #IgHTS for #MRD measurement in mature B-cell #lymphomas. #lymsm
ashpublications.org/bloodadvances/… High sensitivity of MRD testing is critical for detecting residual disease, but as sensitivity has increased, the impact on clinical specificity has been less clear.

Do you remember the vigorous April 2023 discussion after #ODAC vote & #FDA approval of #polatuzumab for #DLBCL & #HGBCL? Well, with @ac_palmer & Dave Kurtz, we now tackle this more through meta-analysis @NEJM… 1/n
nejm.org/doi/full/10.10… After >20 years, #POLARIX showed pola-R-CHP as the 1st regimen of available agents to improve PFS over R-CHOP among randomized blinded trials… 2/n

Very excited to share our new study on determinants of resistance to anti-CD19 CAR T-cells (CART19) in large B-cell lymphomas (LBCLs)! Out today in @Cancer_Cell /1

cell.com/cancer-cell/fu… A fantastic collaboration from @StanfordMed and @StanfordCancer led by Brian Sworder, David Kurtz, @StefanAlig, and Matthew Frank with David Miklos & @max_diehn to help improve outcomes following CAR T-cell therapy in lymphomas & beyond /2

Delighted to share our new study nature.com/articles/s4158… introducing PhasED-Seq out today @NatureBiotech. A fantastic collaboration from @StanfordMedicine led by Dave_Kurtz & Joanne Soo with @max_diehn to help transform #cancer interception & monitoring by improving #LiquidBiopsy #ctDNA detection of #MRD.